Tirzepatide Compounding & Shortage Update

Tirzepatide (marketed as Mounjaro® and Zepbound® by Eli Lilly) is a dual GIP/GLP-1 receptor agonist that has experienced significant supply challenges due to high demand.

Compounded Tirzepatide Availability

When tirzepatide is on the FDA Drug Shortage List, licensed 503A compounding pharmacies can legally compound tirzepatide for individual patients. Promise Pharmacy compounds tirzepatide in multiple concentrations to support standard titration protocols.

Current status: In stock and available for provider accounts. Contact your account manager for the latest regulatory status.

Switching from Branded to Compounded

Patients on branded Mounjaro® or Zepbound® can typically transition to compounded tirzepatide at equivalent doses. Key considerations:

• Maintain the same dose and titration schedule
• Compounded tirzepatide is subcutaneous injection, same route as branded
• Our pharmacists can assist with transition protocol questions
• Third-party potency testing ensures accurate dosing

Quality & Testing

All compounded tirzepatide from Promise Pharmacy undergoes:

• Third-party potency testing (HPLC)
• Sterility testing
• Endotoxin (LAL) testing
• Certificate of Analysis documentation